Figure 1. Co-deletion of CDKN2A and MIR-491 relieves inhibition of oncogenic pathways and drives multiple hallmarks of tumorigenesis.

While therapeutic targeting of tumor suppressor gene loss is not a viable therapeutic strategy, tumor suppressive miRNA can be targeted by direct delivery of miRNA mimics or by using delivery methods such as nanoparticles or mesenchymal stem cells.